Literature DB >> 10739785

Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis.

K N Lai1, K B Lai, C W Lam, T M Chan, F K Li, J C Leung.   

Abstract

Continuous ambulatory peritoneal dialysis (CAPD) has emerged as an important dialysis treatment modality worldwide. One of the major complications is bacterial peritonitis, which may result in subsequent technique failure because of loss of peritoneal clearance or peritoneal fibrosis. Bacterial peritonitis leads to the release of proinflammatory cytokines from resident and infiltrating cells in the peritoneal cavity. We studied 35 patients undergoing CAPD with acute bacterial peritonitis. All patients treated with antibiotics for 2 weeks after the clinical diagnosis of peritonitis had a good recovery. Peritoneal dialysate effluent (PDE) was collected on days 1, 3, 5, 10, 21, and 42 after the start of treatment. Cell populations were monitored by flow cytometry. PDE levels of interleukin-1beta (IL-1), IL-6, transforming growth factor-beta (TGF-beta), and basic fibroblast growth factor (FGF) were measured by enzyme-linked immunosorbent assay. Gene transcription of TGF-beta in macrophages from PDE was measured by quantitative polymerase chain reaction. Bacterial peritonitis was associated with a sharp increase in total cell and neutrophil counts (400-fold) in PDE up to 3 weeks after peritonitis despite clinical remission (P < 0.0001). There was an increased absolute number of macrophages during the first 3 weeks despite the reduced percentage of macrophages among total cells in PDE compared with noninfective PDE. There was a progressive increase in the percentage of mesothelial cells or dead cells in the total cell population in PDE over the entire 6-week period. PDE levels of IL-1, IL-6, TGF-beta, and FGF increased markedly on day 1 before their levels decreased gradually. PDE levels of these cytokines or growth factors were significantly greater than those in noninfective PDE (n = 76) throughout the study period (P < 0.01). Similarly, TGF-beta complementary DNA (cDNA) molecules per macrophage were significantly greater than those of macrophages in noninfective PDE throughout this period (P < 0.01). There was no significant correlation between PDE levels of TGF-beta and TGF-beta cDNA molecules per macrophage, suggesting that peritoneal macrophages are not the only source of TGF-beta in PDE. We conclude there is an active release of proinflammatory cytokines and sclerogenic growth factors through at least 6 weeks despite apparent clinical remission of peritonitis. The peritoneal cytokine networks after peritonitis may potentially affect the physiological properties of the peritoneal membrane.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739785     DOI: 10.1016/s0272-6386(00)70011-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  35 in total

1.  Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Authors:  Sylvie Opatrna; Daniel Lysak; Ladislav Trefil; Clare Parker; Nicholas Topley
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

2.  Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

Authors:  Anne-Catherine Raby; Chantal S Colmont; Ann Kift-Morgan; Jörg Köhl; Matthias Eberl; Donald Fraser; Nicholas Topley; Mario O Labéta
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

3.  TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis.

Authors:  Hiroshi Kinashi; Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Takeshi Terabayashi; Fumiko Nagura; Ryohei Hattori; Yoshihisa Matsukawa; Tomohiro Mizuno; Yukihiro Noda; Hayato Nishimura; Ryosuke Nishio; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

4.  Is It Beneficial to Convert to a Neutral-pH Bicarbonate/Lactate-Buffered PD Solution in Long-Term CAPD Patients? A Single-Center Prospective Study.

Authors:  Tae-Hyun Yoo; Mi Jung Lee; Hyung Jung Oh; Jung Tak Park; Seung Hyeok Han; Shin-Wook Kang; Dae Suk Han
Journal:  Perit Dial Int       Date:  2015 May-Jun       Impact factor: 1.756

5.  Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients.

Authors:  Hirotaka Nakamoto; Chieko Hamada; Tetsutaro Shimaoka; Yoshimi Sekiguchi; Hiroaki Io; Kayo Kaneko; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Artif Organs       Date:  2013-12-14       Impact factor: 1.731

6.  The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.

Authors:  Lei Zhang; Jian-Bing Hao; Lian-Sheng Ren; Jiu-Li Ding; Li-Rong Hao
Journal:  Lab Invest       Date:  2014-05-26       Impact factor: 5.662

7.  Roles of neutrophil gelatinase-associated lipocalin in continuous ambulatory peritoneal dialysis-related peritonitis.

Authors:  Joseph C K Leung; Man Fai Lam; Sydney C W Tang; Loretta Y Y Chan; K Y Tam; Terence P S Yip; Kar Neng Lai
Journal:  J Clin Immunol       Date:  2009-01-16       Impact factor: 8.317

8.  Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats.

Authors:  Fengxin Zhu; Tang Li; Fanghua Qiu; Jinjin Fan; Qin Zhou; Xuebing Ding; Jing Nie; Xueqing Yu
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

Review 9.  Peritoneal adipocytes and their role in inflammation during peritoneal dialysis.

Authors:  Kar Neng Lai; Joseph C K Leung
Journal:  Mediators Inflamm       Date:  2010-05-05       Impact factor: 4.711

10.  Heme oxygenase-1 attenuates epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.

Authors:  Kitae Bang; Jinuk Jeong; Jong Ho Shin; Ju Hyung Kang; Chang Nam Kim; Hye-Jung Yeom; Myeong Ok Yoon; Jaeseok Yang; Curie Ahn; Jong-Ik Hwang; Mee Young Park; Joo-Heon Kim; Kang Wook Lee
Journal:  Clin Exp Nephrol       Date:  2012-11-14       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.